The post Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown appeared on BitcoinEthereumNews.com. The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk. Denmark has recorded strong annual growth in recent years, with its economy expanding 3.7% last year, boosted in large part by pharmaceutical exports. Danish pharma giant Novo Nordisk makes blockbuster weight management drugs Ozempic and Wegovy. The economy ministry noted that Denmark’s U.S. exports fell significantly in early 2025 after a huge spike in late 2024, due to both inventory build-up and increased competition in the weight loss drug market, which has seen Novo lose market share. Generic medicines are also squeezing sales opportunities in the U.S., it said. Europe’s pharmaceutical sector has been rocked this year by the threat of sky-high U.S. tariffs, though some certainty has now been provided by the EU-U.S. trade deal. The Danish economy ministry said U.S. tariffs had also weighed on its growth forecast. “Growth in the first quarter of 2025 has also been weaker than previously expected. Together with the American tariff increases and downwardly adjusted expectations for the pharmaceutical industry, this has given rise to a significant downward adjustment of the estimate for GDP growth in 2025,” it said in a statement, according to Google translate. The ministry stressed, however, that despite the lower growth forecast, its economy remains strong overall, with high employment and inflation expected to be below 2% on an annual basis. It meanwhile revised its growth forecast for 2026 higher, to 2.1% from 1.4%, on expectations… The post Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown appeared on BitcoinEthereumNews.com. The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk. Denmark has recorded strong annual growth in recent years, with its economy expanding 3.7% last year, boosted in large part by pharmaceutical exports. Danish pharma giant Novo Nordisk makes blockbuster weight management drugs Ozempic and Wegovy. The economy ministry noted that Denmark’s U.S. exports fell significantly in early 2025 after a huge spike in late 2024, due to both inventory build-up and increased competition in the weight loss drug market, which has seen Novo lose market share. Generic medicines are also squeezing sales opportunities in the U.S., it said. Europe’s pharmaceutical sector has been rocked this year by the threat of sky-high U.S. tariffs, though some certainty has now been provided by the EU-U.S. trade deal. The Danish economy ministry said U.S. tariffs had also weighed on its growth forecast. “Growth in the first quarter of 2025 has also been weaker than previously expected. Together with the American tariff increases and downwardly adjusted expectations for the pharmaceutical industry, this has given rise to a significant downward adjustment of the estimate for GDP growth in 2025,” it said in a statement, according to Google translate. The ministry stressed, however, that despite the lower growth forecast, its economy remains strong overall, with high employment and inflation expected to be below 2% on an annual basis. It meanwhile revised its growth forecast for 2026 higher, to 2.1% from 1.4%, on expectations…

Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.

Mads Claus Rasmussen | Afp | Getty Images

Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk.

Denmark has recorded strong annual growth in recent years, with its economy expanding 3.7% last year, boosted in large part by pharmaceutical exports.

Danish pharma giant Novo Nordisk makes blockbuster weight management drugs Ozempic and Wegovy.

The economy ministry noted that Denmark’s U.S. exports fell significantly in early 2025 after a huge spike in late 2024, due to both inventory build-up and increased competition in the weight loss drug market, which has seen Novo lose market share.

Generic medicines are also squeezing sales opportunities in the U.S., it said.

Europe’s pharmaceutical sector has been rocked this year by the threat of sky-high U.S. tariffs, though some certainty has now been provided by the EU-U.S. trade deal.

The Danish economy ministry said U.S. tariffs had also weighed on its growth forecast.

“Growth in the first quarter of 2025 has also been weaker than previously expected. Together with the American tariff increases and downwardly adjusted expectations for the pharmaceutical industry, this has given rise to a significant downward adjustment of the estimate for GDP growth in 2025,” it said in a statement, according to Google translate.

The ministry stressed, however, that despite the lower growth forecast, its economy remains strong overall, with high employment and inflation expected to be below 2% on an annual basis.

It meanwhile revised its growth forecast for 2026 higher, to 2.1% from 1.4%, on expectations for higher private and public consumption.

This is a breaking news story and will be updated shortly.

Source: https://www.cnbc.com/2025/08/29/denmark-slashes-2025-growth-forecast-amid-novo-nordisk-slowdown-.html

Market Opportunity
RISE Logo
RISE Price(RISE)
$0.005924
$0.005924$0.005924
-1.95%
USD
RISE (RISE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Will Bitcoin Make a New All-Time High Soon? Here’s What Users Think

Will Bitcoin Make a New All-Time High Soon? Here’s What Users Think

The post Will Bitcoin Make a New All-Time High Soon? Here’s What Users Think appeared on BitcoinEthereumNews.com. Bitcoin has broken out of a major horizontal channel
Share
BitcoinEthereumNews2026/01/16 05:27
SWIFT Tests Societe Generale’s MiCA-Compliant euro Stablecoin for Tokenized Bond Settlement

SWIFT Tests Societe Generale’s MiCA-Compliant euro Stablecoin for Tokenized Bond Settlement

The global banking network SWIFT successfully completed a pilot program using Societe Generale's regulated euro stablecoin to settle tokenized bonds.
Share
Brave Newcoin2026/01/16 05:30
BetFury is at SBC Summit Lisbon 2025: Affiliate Growth in Focus

BetFury is at SBC Summit Lisbon 2025: Affiliate Growth in Focus

The post BetFury is at SBC Summit Lisbon 2025: Affiliate Growth in Focus appeared on BitcoinEthereumNews.com. Press Releases are sponsored content and not a part of Finbold’s editorial content. For a full disclaimer, please . Crypto assets/products can be highly risky. Never invest unless you’re prepared to lose all the money you invest. Curacao, Curacao, September 17th, 2025, Chainwire BetFury steps onto the stage of SBC Summit Lisbon 2025 — one of the key gatherings in the iGaming calendar. From 16 to 18 September, the platform showcases its brand strength, deepens affiliate connections, and outlines its plans for global expansion. BetFury continues to play a role in the evolving crypto and iGaming partnership landscape. BetFury’s Participation at SBC Summit The SBC Summit gathers over 25,000 delegates, including 6,000+ affiliates — the largest concentration of affiliate professionals in iGaming. For BetFury, this isn’t just visibility, it’s a strategic chance to present its Affiliate Program to the right audience. Face-to-face meetings, dedicated networking zones, and affiliate-focused sessions make Lisbon the ideal ground to build new partnerships and strengthen existing ones. BetFury Meets Affiliate Leaders at its Massive Stand BetFury arrives at the summit with a massive stand placed right in the center of the Affiliate zone. Designed as a true meeting hub, the stand combines large LED screens, a sleek interior, and the best coffee at the event — but its core mission goes far beyond style. Here, BetFury’s team welcomes partners and affiliates to discuss tailored collaborations, explore growth opportunities across multiple GEOs, and expand its global Affiliate Program. To make the experience even more engaging, the stand also hosts: Affiliate Lottery — a branded drum filled with exclusive offers and personalized deals for affiliates. Merch Kits — premium giveaways to boost brand recognition and leave visitors with a lasting conference memory. Besides, at SBC Summit Lisbon, attendees have a chance to meet the BetFury team along…
Share
BitcoinEthereumNews2025/09/18 01:20